EDG-5506-201

Recruiting
99 years and younger
All
Phase N/A
1 Location

Brief description of study

This is a multicenter, randomized, Phase 2, double-blind, placebo-controlled study to evaluate the effect of EDG-5506 on the safety, PK, biomarkers, and functional measures in adult and adolescent participants with BMD. This randomized, double-blind, placebo-controlled study will evaluate the safety, pharmacokinetics (PK), and efficacy of EDG-5506 in adults and adolescents with genetically confirmed BMD.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: - 99 Years
  • Gender: All

TBD

Updated on 03 Sep 2024. Study ID: 853514

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center